- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01880411
Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity PEK Fusion Protein Vaccine
Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity of a Three Dose Regimen of Escalating Doses of PEK Fusion Protein Vaccine (PEK + GPI-0100) in Patients With LSIL or HSIL
Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity of a Three Dose Regimen of Escalating Doses of PEK Fusion Protein Vaccine in Women with LSIL or HSIL.
PEK fusion protein vaccine (PEK + GPI-0100) is safe and well tolerated in patients with low-grade squamous intraepithelial lesions (LSIL) or high grade squamous intraepithelial lesions (HSIL) of the cervix and induces a measurable immune response.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female age 18 to 45 years
- Written informed consent in accordance with institutional guidelines
- Negative pregnancy test
- LSIL or HSIL on Papanicolaou (PAP) smear within the prior 6-8 weeks
- Normal electrocardiogram (ECG), laboratory values (chemistry, complete blood count) and urinalysis, as judged by Grade 0-1 as per National Cancer Institute Common Toxicity Criteria (NCI-CTC) performed up to 30 days prior to administration of study treatment.
- Body mass index (BMI) ≤32 kg/m2
- Women of child-bearing potential (WOCBP) agree to use two forms of medically effective contraception (e.g. hormonal contraception, intrauterine device, barrier method, spermicide, etc…) during the study and for at least 12 weeks following the completion of treatment. Patients agree to inform the investigator immediately if they become pregnant during the study or within 12 weeks following completion of treatment and to provide information about the pregnancy, delivery and health of the infant until the age of one month.
- Able and willing to comply with all study procedures
Exclusion Criteria:
- Active infection with herpes simplex virus (HSV)
- Positive serologic test for human immunodeficiency virus (HIV), Hepatitis C virus (HCV), or Hepatitis B surface antigen (HBsa)
- Pregnant or breast-feeding
- History of any prior cervical surgical treatment
- History of any active autoimmune disease or current medical condition requiring the use of systemic or topical corticosteroids (excluding steroid containing eye drops or inhaled steroids) or other immunosuppressive agents within 4 weeks prior to enrollment
- History of cancer (excluding basal cell carcinoma of the skin)
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Administration of any blood product within 3 months of enrollment
- Administration of any vaccine within 6 weeks of enrollment
- Active infection requiring antimicrobial treatment
- Participation in any study with an investigational compound or device within 30 days prior to signing informed consent
- Any hematologic disorder involving platelets or clotting abnormalities or any condition requiring treatment with transfusions, anticoagulants or platelet inhibitors
- Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study protocol
- Any condition which, in the opinion of the investigator, would limit the evaluation of the patient.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PEK Fusion Protein Vaccine
PEK Fusion Protein Vaccine Injection 0.1mg, 0.3mg and 1.2mg
One injection at one week intervals
|
PEK (PE-E7-K3), a recombinant protein combined with GPI-0100 adjuvant
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with adverse events.
Time Frame: 6 Months
|
6 Months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HBPEKVPI001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Intraepithelial Neoplasia
-
Krankenhaus Barmherzige Schwestern LinzMedical University of ViennaCompletedCervical Intraepithelial Neoplasia Grade 1 | Cervical Intraepithelial Neoplasia Grade 2Austria
-
National Cancer Institute (NCI)TerminatedCervical Cancer | Cervical Intraepithelial Neoplasia Grade 2 | Cervical Intraepithelial Neoplasia Grade 3United States
-
Genexine, Inc.CompletedCervical Intraepithelial Neoplasia 3Korea, Republic of
-
Nykode Therapeutics ASATheradex; Vaccibody ASCompletedHigh Grade Cervical Intraepithelial NeoplasiaGermany
-
University of Alabama at BirminghamNational Cancer Institute (NCI)CompletedHigh-grade Cervical Intraepithelial NeoplasiaUnited States
-
National Cancer Institute (NCI)Active, not recruitingCervical Intraepithelial Neoplasia Grade 2/3 | High Grade Cervical Intraepithelial Neoplasia | Cervical Squamous Cell Carcinoma In Situ | Cervical Squamous Intraepithelial Neoplasia 2United States
-
Brookdale University Hospital Medical CenterUnknownCarcinoma in Situ of Uterine Cervix | Cervical Intraepithelial Neoplasias | High Grade Cervical Intraepithelial NeoplasiaUnited States
-
BioLeaders CorporationUnknownCervical Intraepithelial Neoplasia Grade 2/3Korea, Republic of
-
University Medical Centre MariborRecruitingCervical Intraepithelial Neoplasia Grade 2 | DNA MethylationSlovenia
-
Onconix, IncUnknownCervical Cancer | Cervical Intraepithelial Neoplasia III | Cervical Intraepithelial Neoplasia IIUnited States
Clinical Trials on PEK Fusion Protein Vaccine
-
THEVAX Genetics VaccineClinical Research Management, Inc.UnknownHuman Papillomavirus | High-Grade Squamous Intraepithelial LesionsUnited States
-
Livzon Pharmaceutical Group Inc.Active, not recruiting
-
Livzon Pharmaceutical Group Inc.Active, not recruiting
-
Livzon Pharmaceutical Group Inc.Simoon Record Pharma Information Consulting Co., Ltd.; Guangdong Center for...Completed
-
Livzon Pharmaceutical Group Inc.Active, not recruiting
-
Livzon Pharmaceutical Group Inc.Active, not recruiting
-
Livzon Pharmaceutical Group Inc.Active, not recruitingCOVID-19 PandemicPhilippines, Indonesia, Russian Federation
-
Livzon Pharmaceutical Group Inc.CompletedCOVID-19 PandemicMalaysia, Pakistan
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBlastic Plasmacytoid Dendritic Cell NeoplasmUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedLeukemiaUnited States